BeOne Medicines (ONC) director awarded 18,980 RSU-based Ordinary Shares

Rhea-AI Filing Summary

Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. director Margaret Dugan received an equity award of 18,980 Ordinary Shares on June 11, 2026, reported at a price of $0.0000 per share. These represent securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Dugan directly holds 73,164 Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dugan Margaret

Role null

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,980	$0.00	--

Holdings After Transaction: Ordinary Shares — 73,164 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 18,980 Ordinary Shares Grant price: $0.0000 per share Shares held after grant: 73,164 Ordinary Shares

3 metrics

Shares granted 18,980 Ordinary Shares Equity award on June 11, 2026

Grant price $0.0000 per share Reported transaction price for the award

Shares held after grant 73,164 Ordinary Shares Total direct holdings following transaction

Key Terms

restricted share units, vested, Independent Non-Executive Director Compensation Policy

3 terms

restricted share units financial

"Represents securities underlying restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

vested financial

"shall become fully vested on the earlier to occur of the first anniversary"

Independent Non-Executive Director Compensation Policy financial

"triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugan Margaret

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		18,980	A	$0	73,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BeOne Medicines (ONC) report for Margaret Dugan?

BeOne Medicines reported that director Margaret Dugan received an equity award of 18,980 Ordinary Shares. The award is structured as restricted share units that convert into shares, increasing her direct holdings to 73,164 Ordinary Shares after the transaction.

Was the BeOne Medicines (ONC) transaction a market purchase or a share grant?

The transaction was a share grant, not a market purchase. It is coded as a grant or award acquisition at a price of $0.0000 per share and is tied to restricted share units granted under the company’s Independent Non-Executive Director Compensation Policy.

How many BeOne Medicines (ONC) shares does Margaret Dugan hold after this Form 4?

After this transaction, Margaret Dugan directly holds 73,164 Ordinary Shares of BeOne Medicines. This total reflects the addition of 18,980 shares underlying restricted share units granted on June 11, 2026, as disclosed in the Form 4 filing.

How do the restricted share units for BeOne Medicines (ONC) director vest?

The restricted share units vest fully on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if the director leaves the board, unless accelerated vesting is triggered under the company’s compensation policy.

Does the BeOne Medicines (ONC) director have to stay on the board to vest the RSUs?

Yes, continued board service is required for vesting. All vesting ceases if the director resigns or otherwise stops serving, unless a specified triggering event causes accelerated vesting under BeOne Medicines’ Independent Non-Executive Director Compensation Policy.